Real-world evidence on the use of daratumumab, bortezomib and dexamethasone (DVd) in lenalidomide-refractory myeloma patients: subgroup analysis of the multicenter retrospective experience by “rete ematologica pugliese”Giuseppe Mele, Domenico Pastore, Nicola Cascavilla et al.|Leukemia & lymphoma/Leukemia and lymphoma|2023Cited by 2